Experiments in cultured cells and mice identify TRIM2 as a brake on antiviral signalling during influenza A infection. The protein promoted degradation of a viral sensor and an interferon signalling component. Removing its gene reduced viral burden and lung injury in mice. The peer-reviewed findings concern experimental models and establish no safe or effective intervention for people.
Mice lacking the TRIM2 gene had lower viral loads and less lung injury after experimental influenza A infection. Survival outcomes also improved under the tested conditions. Increasing TRIM2 in cultured cells favoured viral replication, while reducing its activity had the opposite effect. The peer-reviewed investigation used cells and genetically modified mice to examine a host protein that can weaken antiviral defence.[1]
Interferons are signalling proteins that change gene activity during infection. They can increase TRIM2 production, even though its action in these experiments supported the virus. TRIM2 interacted with MDA5, a protein that senses viral material, and STAT2, a component transmitting interferon signals. The results support ubiquitin-mediated marking and degradation of these targets, weakening both the production of interferon and the cellular response to its signal.[1]
Protein-interaction tests and genetic manipulations helped connect the proposed mechanism to infection outcomes. The team used PR8, an H1N1 influenza A strain, in the experiments. Some molecular details still require validation, including direct chemical mapping of the implicated MDA5 site. The core mechanism was not independently tested in primary cells. TRIM2 also serves other tissues, so removing its gene in mice establishes no safe or effective treatment strategy for people.[1]
